BR112014013704B1 - Composição farmacêutica e método para se obter a substância ativa da mesma - Google Patents

Composição farmacêutica e método para se obter a substância ativa da mesma Download PDF

Info

Publication number
BR112014013704B1
BR112014013704B1 BR112014013704-8A BR112014013704A BR112014013704B1 BR 112014013704 B1 BR112014013704 B1 BR 112014013704B1 BR 112014013704 A BR112014013704 A BR 112014013704A BR 112014013704 B1 BR112014013704 B1 BR 112014013704B1
Authority
BR
Brazil
Prior art keywords
seq
mutated
protein
amino acid
env protein
Prior art date
Application number
BR112014013704-8A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014013704A2 (pt
Inventor
Thierry Heidmann
Original Assignee
Viroxis S.A.S.
Centre National De La Recherche Scientifique
Institut Gustave Roussy
Universite Paris-Saclay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viroxis S.A.S., Centre National De La Recherche Scientifique, Institut Gustave Roussy, Universite Paris-Saclay filed Critical Viroxis S.A.S.
Publication of BR112014013704A2 publication Critical patent/BR112014013704A2/pt
Publication of BR112014013704B1 publication Critical patent/BR112014013704B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112014013704-8A 2011-12-07 2012-12-07 Composição farmacêutica e método para se obter a substância ativa da mesma BR112014013704B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11306625.2 2011-12-07
EP11306625 2011-12-07
PCT/EP2012/074835 WO2013083799A1 (en) 2011-12-07 2012-12-07 Mutated lentiviral env proteins and their use as drugs

Publications (2)

Publication Number Publication Date
BR112014013704A2 BR112014013704A2 (pt) 2021-02-17
BR112014013704B1 true BR112014013704B1 (pt) 2023-01-31

Family

ID=47435901

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014013704-8A BR112014013704B1 (pt) 2011-12-07 2012-12-07 Composição farmacêutica e método para se obter a substância ativa da mesma

Country Status (16)

Country Link
US (1) US9682137B2 (enExample)
EP (1) EP2788372B1 (enExample)
JP (2) JP6415324B2 (enExample)
KR (1) KR102059918B1 (enExample)
CN (1) CN104169295B (enExample)
AU (1) AU2012350258B2 (enExample)
BR (1) BR112014013704B1 (enExample)
CA (1) CA2856180C (enExample)
DK (1) DK2788372T3 (enExample)
ES (1) ES2748864T3 (enExample)
IL (1) IL232926B (enExample)
IN (1) IN2014CN04927A (enExample)
MX (1) MX350689B (enExample)
RU (1) RU2654673C2 (enExample)
WO (1) WO2013083799A1 (enExample)
ZA (1) ZA201403617B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3676285B1 (en) * 2017-09-01 2025-11-05 InProTher ApS A vaccine for use in the prophylaxis and/or treatment of a disease
AU2022208199A1 (en) 2021-01-13 2023-07-13 Centre National De La Recherche Scientifique Measles-hiv or measles-htlv vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201750A1 (en) * 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
CA2520768A1 (en) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
WO2005095442A1 (en) 2004-03-30 2005-10-13 Institut Gustave Roussy Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins
DK1778282T3 (en) 2004-08-17 2016-06-06 Roussy Inst Gustave Mutated HIV NEF TO MODULATION OF IMMUNITY
US20110305749A1 (en) 2008-08-28 2011-12-15 Mogens Ryttergaard Duch HIV-1 Envelope Polypeptides for HIV Vaccine
RU2426788C1 (ru) * 2010-03-01 2011-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ЦНИИЭ Роспотребнадзора) Генетические конструкции для антивич-терапии

Also Published As

Publication number Publication date
JP2018150370A (ja) 2018-09-27
IL232926A0 (en) 2014-07-31
AU2012350258A1 (en) 2014-06-05
IL232926B (en) 2019-01-31
US9682137B2 (en) 2017-06-20
IN2014CN04927A (enExample) 2015-09-18
DK2788372T3 (da) 2019-10-14
RU2654673C2 (ru) 2018-05-21
US20140294880A1 (en) 2014-10-02
AU2012350258B2 (en) 2017-03-02
AU2012350258A8 (en) 2014-07-17
MX350689B (es) 2017-09-13
EP2788372B1 (en) 2019-07-10
CA2856180A1 (en) 2013-06-13
KR20140116091A (ko) 2014-10-01
RU2014127521A (ru) 2016-02-10
CA2856180C (en) 2022-09-06
MX2014006744A (es) 2014-12-08
EP2788372A1 (en) 2014-10-15
CN104169295B (zh) 2020-07-28
CN104169295A (zh) 2014-11-26
JP6415324B2 (ja) 2018-10-31
ES2748864T3 (es) 2020-03-18
KR102059918B1 (ko) 2020-02-11
ZA201403617B (en) 2015-07-29
JP2015505836A (ja) 2015-02-26
WO2013083799A1 (en) 2013-06-13
BR112014013704A2 (pt) 2021-02-17

Similar Documents

Publication Publication Date Title
JP4805511B2 (ja) Ｈｉｖに対する免疫応答における改善、または免疫応答に関する改善
EP3967323A2 (en) Hiv vaccine
PL188641B1 (pl) Szczepionka polienv przeciwko HIV, sposób wytwarzania szczepionki polienv,zastosowanie szczepionki polienv,zastosowanie przynajmniej jednego rekombinowanego białka env HIV lub przynajmniej jednego wektora DNA, który koduje ekspresję rekombinowanego białka env HIV, plazmid bifunkcjonalny.
CA2505583C (en) Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
SK287382B6 (sk) Očkovacia kompozícia
Hasenkrug et al. Immunoprotective determinants in friend murine leukemia virus envelope protein
JP2007534302A (ja) Ｈｉｖ医薬
BR112014013704B1 (pt) Composição farmacêutica e método para se obter a substância ativa da mesma
EP3004143B1 (en) Mutated non-primate lentiviral env proteins and their use as drugs
PT85093B (pt) Vector viral e processo para a preparacao de adn recombinante codificando para a proteina f do virus agente causador da s.i.d.a.
US20110189216A1 (en) Compositions and Methods for the Treatment and Prophylaxis of Multiple Strains and Subtypes of HIV-1
US9636396B2 (en) Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties
US11590219B2 (en) Compositions and methods for promoting immune responses to human immunodeficiency virus
CA2548483A1 (en) Induction of antiviral neutralizing antibodies in humans and animals
US20170107260A1 (en) Mosaic hiv-1 sequences and uses thereof
BR122025007011A2 (pt) Nanopartícula, vacina combinada, nanocluster de mrna, composição de nanopartículas, peptídeo imunogênico e composição imunogênica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: VIROXIS S.A.S. (FR) ; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) ; INSTITUT GUSTAVE ROUSSY (FR) ; UNIVERSITE PARIS-SACLAY (FR)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/12/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.